Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial - Braulke, Friederike; Nolte, Florian; Hofmann, Wolf-Karsten; Schlenk, Richard Friedrich (Annals of hematology, 2017)
First online: 03 April 2017